CUBEBIO Co., Ltd. Entered Into Terms Relating To A Potential Business Combination With Mountain Crest Acquisition Corp. V
CUBEBIO Co., Ltd. Entered Into Terms Relating To A Potential Business Combination With Mountain Crest Acquisition Corp. V
Mountain Crest Acquisition Corp. V, a Delaware corporation ("Mountain Crest V"), that is a Nasdaq-listed (NASDAQ:MCAG) special purpose acquisition company ("SPAC"), and CUBEBIO Co., Ltd., a Korea-based company ("CUBEBIO"), which has an innovative technology that diagnoses cancer at an early stage using urine, today announced that the parties entered into a non-binding term sheet on April 26, 2024 for a proposed business combination through which CUBEBIO plans to become a public company with its securities listed on The Nasdaq Stock Market. Mountain Crest V is the fifth vehicle in the Mountain Crest family of SPACs, the management of which has successfully completed four prior SPAC business combinations.
特拉华州公司（“Mountain Crest V”）是一家在纳斯达克上市（纳斯达克股票代码：MCAG）的特殊目的收购公司（“SPAC”）Mountain Crest Acquisition Corp. V.（“Mountain Crest V”）和总部位于韩国的公司（“CUBEBIO”）CubeBIO有限公司（“CUBEBIO”）今天宣布，双方签订了一份不具约束力的条款表。2024年4月26日，CUBEBIO计划通过该合并成为一家上市公司，其证券在纳斯达克股票市场上市。Mountain Crest V是Mountain Crest系列SPAC中的第五款车辆，该公司的管理层已经成功完成了之前的四次SPAC业务合并。
Based on the non-binding term sheet, the pre-transaction equity value of CUBEBIO for the proposed business combination is $620 million, subject to adjustment depending on additional due diligence by Mountain Crest V and market conditions.
根据不具约束力的条款表，CUBEBIO在拟议业务合并中的交易前股权价值为6.2亿美元，可能会根据Mountain Crest V的额外尽职调查和市场状况进行调整。
Global Fund LLC, a Washington D.C.-based advisory firm specializing in SPAC and DeSPAC transactions in the U.S., has been engaged by CUBEBIO to advise CUBEBIO in connection with the proposed business combination.
Global Fund LLC是一家总部位于华盛顿特区的专门从事美国SPAC和DesPac交易的咨询公司，已受CUBEBIO聘请，为CUBEBIO就拟议的业务合并向CUBEBIO提供建议。
Dr. Suying Liu, Chairman, CEO and CFO of Mountain Crest V commented, "CUBEBIO's innovative diagnostic technology for cancer detection and active commercialization with contract in place point to significant growth potential. We are excited to be partnering with CUBEBIO on this proposed business combination."
Mountain Crest V董事长、首席执行官兼首席财务官刘素英博士评论说：“CUBEBIO用于癌症检测的创新诊断技术和已签订合同的积极商业化表明了巨大的增长潜力。我们很高兴能与CUBEBIO合作进行这项拟议的业务合并。”
Eun-jong Choi, CEO of CUBEBIO emphasized, "We expect to execute a definitive merger agreement with Mountain Crest V, faithfully carry out the process for completing the business combination, and grow CUBEBIO into a global company by increasing corporate value."
CUBEBIO首席执行官崔恩钟强调说：“我们希望与Mountain Crest V签署最终合并协议，忠实地执行完成业务合并的流程，并通过提高企业价值将CUBEBIO发展成为一家跨国公司。”
译文内容由第三方软件翻译。